ALSO NOTED: Agensys gains $41M of venture funds; Endo patch fails trials; Barrier reports positive data; and much more...

> The therapeutic antibody company Agensys has raised $41 million in its fourth round of venture capital. Duquesne Capital Management and Jafco co-led the round. Release [1]

> Endo Pharmaceuticals has had to withdraw its blueprint for developing a skin patch to treat pain and inflammation patch after it failed two late-stage studies. Endo had expected to file for approval in the first half of next year. Report [2]

> Barrier Therapeutics announced positive results from its completed Phase 2 dose-finding study of Oral Rambazole in moderate to severe psoriasis. Release [3]

> Germany's Eppendorf is taking New Brunswick Scientific private in a deal valued at $110 million. NBS is a provider of biotech research equipment. Release [4]

> Bioheart has boosted the size of its IPO, increasing its expected gain to $45 million. Report [5]

> Amgen has granted Daiichi Sankyo exclusive rights to develop and commercialize denosumab in Japan in post-menopausal osteoporosis and oncology with the potential for additional indications. Release [6]

> Labopharm and Paladin Labs announced that they have completed a licensing and distribution agreement which grants Paladin the exclusive right to market Labopharm's once-daily tramadol product in Canada. Labopharm will retain co-promotion rights. Release [7]

> Pharmasset earned a $7.5 million payday from Roche in their collaboration on a new therapy for hepatitis C. Release [8]

> Genentech has once again beat The Street, seeing earnings swell 41 percent in the second quarter. Report [9]

And Finally... A pilot program is paying doctors a bonus for saving Medicare money. Article [10]